1104P Health-related quality of life (HRQOL) in patients with ALK+ non-small cell lung cancer (NSCLC) in the phase III CROWN study

In the randomized, phase III CROWN study, lorlatinib (LOR), a brain-penetrant third generation ALK tyrosine kinase inhibitor, showed significantly longer progression-free survival and a higher frequency intracranial response than crizotinib (CRIZ) for first-line treatment in patients with ALK+ advanced NSCLC; however, patients taking LOR had a higher incidence of grade 3-4 adverse events. Patient-reported outcomes (PROs) from CROWN (NCT03052608) were analyzed to determine the effects of LOR or CRIZ on HRQOL.